CutisPharma, Inc.

Sep 25, 2019

Katerzia(TM), the First and Only Amlodipine Oral Suspension, 1 mg/mL, is Now Commercially Available for Pediatric Patients 6 Years of Age and Older

Jun 12, 2019

CutisPharma Announces Acquisition Of Silvergate Pharmaceuticals, Name Change To Azurity Pharmaceuticals

Mar 26, 2019

CutisPharma Continues Growth Trajectory with Opening of New Corporate Headquarters, Expansion of Manufacturing Site

Mar 25, 2019

CutisPharma Announces Launch of FIRST®-Atenolol Unit-of-Use Prescription Compounding Kit for Oral Solution

Jan 22, 2019

CutisPharma Announces Launch of FIRST®-Metoprolol Unit-of-Use Prescription Compounding Kit for Oral Solution

Jan 15, 2019

CutisPharma Announces New Management Team Appointments

Apr 02, 2018

CutisPharma Announces Launch Of FIRVANQ(TM) (vancomycin hydrochloride) For Oral Solution

Jan 29, 2018

CutisPharma Announces FDA Approval Of FIRVANQ(TM) For Treatment Of Clostridium Difficile Associated Diarrhea (CDAD) And Staphylococcus Aureus Colitis

Nov 01, 2017

CutisPharma and C Diff Foundation Announce Partnership to Kick Off Clostridium difficile Awareness Month

Aug 01, 2017

CutisPharma Announces Executive Team And Board Appointments